Novartis is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases.
The GTnetwork was established in 2019 with the objective of providing the highest quality education to the wider gene therapy healthcare professional community. Novartis, Inc. believes in the need to engage with a world class faculty, comprised of globally renowned clinicians, academics and pathologists, as well as representatives of the leading rare disease and genetic professional organizations to deliver this education. Some of the contributors may be paid consultants for Novartis, Inc.
The information provided through the GTnetwork is intended for the educational benefit of health care professionals. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing GTnetwork’s educational resources.
Novartis, Inc. makes every effort to include truthful, non-misleading and up-to-date information in content, however, Novartis, Inc. makes no warranties or representations as to its accuracy and assumes no liability or responsibility for any errors or omissions in the content of the material. Neither Novartis, Inc. nor any other party involved in creating, producing or delivering the material is liable for any direct, incidental, consequential, indirect or punitive damages arising out of your access to, or use of, the material.